,
Sakurai, Masatoshi
Okamoto, Shinichiro
Matsumura, Itaru
Murakami, Satsuki
Takizawa, Makiko
Waki, Masato
Hirano, Daiki
Watanabe-Nakaseko, Reiko
Kobayashi, Naoki
Iino, Masaki
Mitsui, Hideki
Ishikawa, Yuichi
Takahashi, Naoto
Kawaguchi, Tatsuya
Suzuki, Ritsuro
Yamamoto, Kazuhito
Kizaki, Masahiro
Ohnishi, Kazunori
Naoe, Tomoki
Akashi, Koichi
Funding for this research was provided by:
Novartis Pharmaceuticals
Bristol-Myers Squibb
Article History
Received: 28 November 2019
Revised: 25 February 2020
Accepted: 26 February 2020
First Online: 9 March 2020
Compliance with ethical standards
:
: M. Sakurai reports personal fees from Bristol-Myers Squibb, Takeda Pharmaceutical, Eisai Pharmaceuticals and Nippon Shinyaku, outside the submitted work; S. Okamoto reports grants and personal fees from Otsuka Pharmaceutical, Novartis Pharmaceuticals, Bristol-Myers Squibb, Astellas Pharma, Kyowa Hakko Kirin and Chugai Pharmaceutical, and personal fees from Pfizer, outside the submitted work; I. Matsumura reports grants and personal fees from Bristol-Myers Squibb, Novartis Pharmaceuticals and Otsuka Pharmaceutical, and personal fees from Pfizer, during the conduct of the study; grants and personal fees from Nippon Shinyaku, Celgene, Pfizer, Ono Pharmaceutical, Shionogi and Takeda Pharmaceutical, grants from Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Asahi Kasei Pharma, Astellas Pharma, Japan Blood Products Organization, Nihon Pharmaceutical, Daiichi Sankyo, and personal fees from AbbVie GK, outside the submitted work;. N. Takahashi reports grants and personal fees from Novartis Pharmaceuticals, Pfizer and Otsuka Pharmaceutical, grants from Kyowa Hakko Kirin, Astellas Pharma, Chugai Pharmaceutical, Asahi Kasei Pharma, Ono Pharmaceutical and Eisai Pharmaceuticals, and personal fees from Bristol-Myers Squibb, outside the submitted work; T. Kawaguchi reports grants and personal fees from MSD, and personal fees from Pfizer, Alexion Pharma and Novartis Pharmaceuticals, outside the submitted work; R. Suzuki reports personal fees from Bristol-Meyer Squib, Novartis Pharmaceuticals, Kyowa Hakko Kirin, Chugai Pharmaceutical, Shionogi, Takeda Pharmaceutical, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Sawai, Celgene, Sumitomo Dainippon Pharma, Eisai Pharmaceuticals, Alexion Pharma, Sanofi, Gilead Sciences, Abbvie Inc., Mundi Pharma, Jazz Pharma, Ono Pharmaceutical and Janssen Pharmaceuticals, outside the submitted work; K. Yamamoto reports grants and personal fees from Astra-Zeneca, Celgene, Chugai Pharmaceutical, Eisai Pharmaceuticals, MSD, Novartis Pharmaceuticals, Ono Pharmaceutical, Takeda Pharmaceutical, Zenyaku, Abbvie Inc., Mundi Pharma and Nippon Shinyaku, grants from ARIAD, Bayer, Gilead Sciences, Solasia Pharma, SymBio and Incyte, and personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Boehringer Ingelheim, HUYA/IQVIA Services Japan, Janssen and Stemline Therapeutics, outside the submitted work; M. Kizaki reports grants from Kyowa Hakko Kirin, Chugai Pharmaceutical and Pfizer, and personal fees from Bristol-Myers Squibb, Celgene, Nippon Shinyaku, Takeda Pharmaceutical and Ono Pharmaceutical, outside the submitted work; T. Naoe reports personal fees from Astellas Pharma, Nippon Shinyaku, Bristol-Myers Squibb, Pfizer, Otsuka Pharmaceutical, FujiFilm and Eisai Pharmaceuticals, outside the submitted work; K. Akashi reports grants and personal fees from Bristol-Myers Squibb, Astellas Pharma, Janssen Pharmaceuticals and Kyowa Hakko Kirin, grants from Canon and Otsuka Pharmaceutical, and personal fees from Novartis Pharmaceuticals, Abbvie Inc., Eisai Pharmaceuticals, Celgene and Chugai Pharmaceutical, outside the submitted work; the other authors have nothing to disclose.